RxDoctor Payments Data

Jasmin Geevarghese

Optometry · West Roxbury, MANPI 1245802859

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 18 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by Oyster Point Pharma, Inc. at 32.3% of the total. Reporting peaked in 2024 at $463 and has fallen 91.4% since, to $40 in 2025. Among optometry clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$641in general payments, 2019–2025

Across 18 payments — averaging $35.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Oyster Point Pharma, Inc.$207
  • Tarsus Pharmaceuticals, Inc.$162
  • AbbVie$114
  • Sun Pharmaceutical Industries Inc.$72
  • Carl Zeiss Meditec, Inc.$33
  • Bausch & Lomb Americas Inc.$20
  • plus $32 from 2 others

What the payments were for

  • Food & beverage$641100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$641 in reported general payments places this provider in the 95th percentile of 100 optometry providers in Massachusetts.

See all optometry providers in Massachusetts

Medicare billing

Part B allowed, 2024
$32,887
Medicare patients
216
Services billed
306

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XiidraLifitegrast17$12,321
TyrvayaVarenicline Tartrate12$8,109
RestasisCyclosporine12$7,568
Cyclosporine19$5,738
LumiganBimatoprost13$4,055
Cosopt PfDorzolamide/Timolol/Pf12$2,376
Brimonidine Tartrate14$1,386
Travoprost11$516
Latanoprost43$439
ErythromycinErythromycin Base14$245
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat15$185
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha13$114

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bausch & Lomb Americas Inc.Xiidra$20$12,32117 claims
AbbVieRestasis, Lumigan$114$11,62325 claims
Oyster Point Pharma, Inc.Tyrvaya$207$8,10912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 100 optometry providers in Massachusetts.

Other optometry in West Roxbury

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →